comparemela.com
Home
Live Updates
Aelis Farma Announces the Inclusion of the 1st Patient in a Phase 2b Study of AEF0117 for the Treatment of Cannabis Use Disorder (CUD) : comparemela.com
Aelis Farma Announces the Inclusion of the 1st Patient in a Phase 2b Study of AEF0117 for the Treatment of Cannabis Use Disorder (CUD)
AEF0117 is the most advanced drug candidate of the new pharmacological class, the CB1-SSi, developed by Aelis Farma. AEF0117 aims to treat disorders related to excessive cannabis use (addiction
Related Keywords
Paris ,
France General ,
France ,
United States ,
French ,
Margaret Haney ,
Nicolas Merigeau ,
Vincenzo Piazza ,
Daelis Farma ,
Frances Levin ,
Magendie Neurocenter ,
Inserm Magendie Neurocenter ,
Inserm Transfert Initiative ,
Mental Health Services Administration ,
National Institutes Of Health ,
Neurology Of The French Academy Sciences ,
Columbia University ,
National Survey On Drug ,
Behavioral Health Statistics ,
Professor Of Psychiatry At Columbia University ,
Signaling Specific ,
Pier Vincenzo Piazza ,
National Institutes ,
Inserm Grand Prix ,
Grand Prix ,
French Academy ,
Nouvelle Aquitaine Region ,
Euronext Paris ,
Mental Health Services ,
Drug Use ,
Substance Abuse ,
Saelis ,
Sarma ,
Nnounces ,
Inclusion ,
Patient ,
Hase ,
Study ,
Ef0117 ,
Treatment ,
Cannabis ,
Disorder ,
comparemela.com © 2020. All Rights Reserved.